Incidence of SARS-CoV-2 infection in a cohort of workers from the University of Porto, Portugal

References

• World Health Organization. Population-based age-stratified seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection, 26 May 2020. Geneva: World Health Organization; 2020.
   Google Scholar
• Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection. Ann Intern Med. 2020;173(5):362–367.
   PubMed Web of Science ®Google Scholar
• Byambasuren O, Dobler CC, Bell K, et al. Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: systematic review. PLoS One. 2021;16(4):e0248946.
   PubMed Web of Science ®Google Scholar
• Kislaya I, Gonçalves P, Barreto M, et al. Seroprevalence of SARS-CoV-2 infection in Portugal in May-July 2020: results of the first national serological survey (ISNCOVID-19). Acta Med Port. 2021;34(2):87–94.
   PubMed Web of Science ®Google Scholar
• Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396(10247):313–319.
   PubMed Web of Science ®Google Scholar
• Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396(10250):535–544.
   PubMed Web of Science ®Google Scholar
• Ulyte A, Radtke T, Abela IA, et al. Clustering and longitudinal change in SARS-CoV-2 seroprevalence in school children in the canton of Zurich, Switzerland: prospective cohort study of 55 schools. BMJ. 2021;372:n616.
   PubMedGoogle Scholar
• Vos ERA, den Hartog G, Schepp RM, et al. Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of The Netherlands during the first epidemic wave. J Epidemiol Community Health. 2021;75(6):489–495.
   Web of Science ®Google Scholar
• Bobrovitz N, Arora RK, Cao C, et al. Global seroprevalence of SARS-CoV-2 antibodies: a systematic review and Meta-analysis. Plos One. 2021;16(6):e0252617.
   PubMed Web of Science ®Google Scholar
• Pérez-Olmeda M, Saugar JM, Fernández-García A, et al. Evolution of antibodies against SARS-CoV-2 over seven months: experience of the Nationwide Seroprevalence ENE-COVID Study in Spain. medRxiv. 2021. 2021.03.11.21253142.
   Google Scholar
• den Hartog G, Vos ERA, van den Hoogen LL, et al. Persistence of antibodies to SARS-CoV-2 in relation to symptoms in a nationwide prospective study. Clin Infect Dis. 2021;73(12):2155–2162.
   PubMed Web of Science ®Google Scholar
• Varona JF, Madurga R, Peñalver F, et al. Kinetics of anti-SARS-CoV-2 antibodies over time. Results of 10 month follow up in over 300 seropositive health care workers. Eur J Intern Med. 2021;89:97–103.
   PubMed Web of Science ®Google Scholar
• Gerhards C, Thiaucourt M, Kittel M, et al. Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection. Int J Infect Dis. 2021;107:221–227.
   PubMed Web of Science ®Google Scholar
• Petersen MS, Hansen CB, Kristiansen MF, et al. SARS-CoV-2 natural antibody response persists for at least 12 months in a nationwide study from the Faroe Islands. Open Forum Infect Dis. 2021;8(8):ofab378.
   PubMed Web of Science ®Google Scholar
• Canto e Castro L, Gomes A, Serrano M, et al. Longitudinal SARS-CoV-2 seroprevalence in Portugal and antibody maintenance 12 months after infection. Eur J Immunol. 2022;52(1):149–1601.
   PubMed Web of Science ®Google Scholar
• Figueiredo-Campos P, Blankenhaus B, Mota C, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. Eur J Immunol. 2020;50(12):2025–2040.
   PubMed Web of Science ®Google Scholar
• Tsitsilonis OE, Paraskevis D, Lianidou E, et al. Seroprevalence of antibodies against SARS-CoV-2 among the personnel and students of the National and Kapodistrian University of Athens, Greece: a preliminary report. Life (Basel). 2020;10(9):214.
   Web of Science ®Google Scholar
• Meireles P, Amaro J, Pinto da Costa J, et al. Prevalence of SARS-CoV-2 antibodies among workers of the public higher education institutions of Porto, Portugal: a cross-sectional study. Occup Environ Med. 2021;78(9):648–653.
   PubMed Web of Science ®Google Scholar
• Milani GP, Rota F, Favero C, et al. Detection of IgM, IgG and SARS-CoV-2 RNA among the personnel of the University of Milan, March through May 2020: the UNICORN study. BMJ Open. 2021;11(3):e046800.
   PubMed Web of Science ®Google Scholar
• Instituto Nacional de Saúde Doutor Ricardo Jorge. Inquérito Serológico Nacional COVID-19 (2.a fase) Relatório de apresentação dos resultados. 2021. Available from: http://repositorio.insa.pt/bitstream/10400.18/7746/1/ISN_COVID-19_relat%c3%b3rio_final07052021.pdf
   Google Scholar
• Kumleben N, Bhopal R, Czypionka T, et al. Test, test, test for COVID-19 antibodies: the importance of sensitivity, specificity and predictive powers. Public Health. 2020;185:88–90.
   PubMed Web of Science ®Google Scholar
• Green MA, García-Fiñana M, Barr B, et al. Evaluating social and spatial inequalities of large scale rapid lateral flow SARS-CoV-2 antigen testing in COVID-19 management: an observational study of Liverpool, UK (November 2020 to January 2021). medRxiv. 2021. 2021.02.10.21251256.
   Google Scholar
• Galanis P, Vraka I, Fragkou D, et al. Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and Meta-analysis. J Hosp Infect. 2021;108:120–134.
   PubMed Web of Science ®Google Scholar
• Amorim Filho L, Szwarcwald CL, Mateos SOG, et al. Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio De Janeiro, Brazil. Rev Saude Publica. 2020;54:69.
   PubMed Web of Science ®Google Scholar
• Costa SF, Giavina-Bianchi P, Buss L, et al. SARS-CoV-2 seroprevalence and risk factors among oligo/asymptomatic healthcare workers (HCW): estimating the impact of community transmission. Clin Infect Dis 2021;73(5):e1214–e1218.
   PubMed Web of Science ®Google Scholar
• Leite A, Leão T, Soares P, et al. A case-control study of contextual factors for SARS-CoV-2 transmission. Front Public Health 2021;9:772782.
   Google Scholar
• Stringhini S, Zaballa M-E, Perez-Saez J, et al. Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak. Lancet Infect Dis. 2021;21(5):600–601.
   PubMedGoogle Scholar
• Balanço Social 2020. Universidade do Porto. 2021. Available from: https://sigarra.up.pt/up/pt/conteudos_service.conteudos_cont?pct_id=33023&pv_cod=49P9a1CaBzaa
   Google Scholar
• Maine GN, Lao KM, Krishnan SM, et al. Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect. J Clin Virol. 2020;133:104663.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li J, Li H, et al. Persistence of SARS-CoV-2-specific antibodies in COVID-19 patients. Int Immunopharmacol. 2021;90:107271.
   PubMed Web of Science ®Google Scholar
• Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. JAMA. 2020;323(22):2249–2251.
   PubMed Web of Science ®Google Scholar